Beta-Cross laps (C-terminal telopeptides of type I collagen, a product of collagen degradation as a result of bone resorption, b-CrossLaps of blood serum, C-terminal telopeptide of serum, CT, b-CrossLaps serum, b-CTx serum)

beta-CrossLaps of blood serum (beta-crosslaps, βCTx) is a degradation product of type 1 collagen, which makes up more than 90% of the organic bone matrix. Normally, small fragments of collagen formed during its degradation enter the bloodstream and are excreted by the kidneys in the urine. Alpha-aspartic acid, which is part of the C-terminal telopeptides, is converted to the β-form (bCTx, β-CrossLaps). Such isomerized telopeptides are specific products of type 1 collagen degradation, their level increases in patients with increased bone resorption. They are specific only to bone tissue. Their determination in the blood has an important advantage, they are not subjected to further catabolism. Under what conditions can the level of type I collagen C-terminal telopeptides increase Bone tissue at any age is metabolically active and in a state of constant change – a remodeling process aimed at eliminating micro-damage, maintaining bone strength, and maintaining mineral homeostasis. Bone remodeling involves two simultaneous, but opposite processes – bone formation and bone resorption, the balance of which depends on the state of phosphorus-calcium metabolism, hormonal influences, age-related changes, etc. and varies with various physiological and pathological conditions. Type I collagen C-terminal telopeptides associated with resorption processes serve as one of the markers of bone metabolism activity, reflecting the activity of the resorption process. With physiologically or pathologically increased bone resorption (for example, in old age, as a result of osteoporosis), as well as with multiple myeloma, hyperparathyroidism, metastatic tumors and other diseases, the rate of degradation of type 1 collagen increases, and, accordingly, the content of its fragments in the blood serum increases. Against the background of therapy aimed at inhibiting bone resorption, the concentration of β-CrossLaps in the blood serum gradually returns to normal (no earlier than after a few weeks). For what purpose Beta-Cross laps (type I collagen C-terminal telopeptides) are determined , the study is prescribed in order to monitor the condition of patients with increased bone resorption, determine the algorithm of therapy, and evaluate its effectiveness. What can affect the result of the study "Beta-Cross laps (C-terminal type I collagen telopeptides)" Various clinical situations affecting the level of bone resorption (hyperparathyroidism, hyperthyroidism) may affect the results of the study. In patients with reduced renal function, the content of β-CrossLaps in the blood serum increases due to a decrease in excretion.